Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
Main Authors: | Campbell, A, Ait-Tahar, K, Patel, S, Barnardo, M, Liggins, A, Caibes, M, Banham, A, Collins, G, Hatton, C, Pulford, K |
---|---|
Format: | Conference item |
Published: |
2010
|
Similar Items
-
PASD1 is a potential multiple myeloma-associated antigen.
by: Sahota, S, et al.
Published: (2006) -
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
by: Cooper, C, et al.
Published: (2006) -
Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
by: Ait-Tahar, K, et al.
Published: (2009) -
Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
by: Ait-Tahar, K, et al.
Published: (2009) -
DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
by: Joseph-Pietras, D, et al.
Published: (2010)